ScripIt is well known that the pharmaceutical industry is unpredictable. Both drug developers themselves and the brokers covering them must do their best to try and predict the performance of their assets
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CytomX, Amgen Decision Follows January
ScripWho: Grünenthal/Valinor Pharma What: Grünenthal is buying privately held US biotech Valinor on the strength of its lone commercial product, Movantik. Why: Grünenthal is acquiring Valinor to gain
ScripThe recent partial success of Vertex Pharmaceuticals Incorporated ’s non-opioid product VX-548 in a pair of acute pain studies positions the product as potentially the first new non-opioid analgesic